600079 人福医药
2025/06 - 中期
人民幣(K¥)
与去年同期
比较
2024/12
人民幣(K¥)
2023/12
人民幣(K¥)
2022/12
人民幣(K¥)
2021/12
人民幣(K¥)
营业总收入12,063,918-6.20%25,435,48424,524,74122,337,71920,548,930
减:营业总成本10,297,053-7.45%22,665,86821,417,05919,851,77518,750,613
    其中:营业成本6,251,176-8.67%14,103,26113,290,99212,615,13811,764,845
               财务费用120,843-22.02%350,704304,519236,944623,308
               资产减值损失(18,073)347.73%(393,861)(61,407)(88,312)(55,124)
公允价值变动收益(1,618)-71.41%112,717136,85543,4177,885
投资收益47,36664.99%133,086206,785835,557306,009
    其中:对联营企业和合营企业的投资收益40,72315.94%68,16159,99222,514132,336
营业利润1,834,5130.79%2,522,0293,447,1743,516,0282,249,040
利润总额1,789,2260.77%2,422,8303,383,8293,426,0532,172,974
减:所得税费用292,052-8.69%644,487568,563354,751354,782
净利润1,497,1742.85%1,778,3432,815,2663,071,3021,818,193
减:非控股权益342,507-0.59%448,598680,781587,194501,047
股东净利润1,154,6673.92%1,329,7452,134,4852,484,1091,317,146

市场价值指针
每股收益 (元) *0.7104.41%0.8201.3201.5400.830
每股派息 (元) *----0.4700.4600.1600.150
每股净资产 (元) *11.2336.05%10.79710.4419.2107.929
审计意见 #--带有强调事项段、持续经营重大不确定性段落、其他信息段落中包含其他信息未更正重大错报说明的无保留意见标准无保留意见标准无保留意见带有强调事项段、持续经营重大不确定性段落、其他信息段落中包含其他信息未更正重大错报说明的无保留意见
回页顶
备注: *未调整数据
#只提供简体内容